Treatment of multiple system atrophy using intravenous ... - Springer Link
Recommend Documents
Jun 10, 2010 - Intravenous bisphosphonate treatment and pregnancy: its effects on mother and infant bone health. S. R. Mastaglia & N. P. Watman & B. Oliveri.
Jun 10, 2010 - onate every 3 months and safe contraception were indicated. Fifteen days after receiving the fourth infusion, the patient informed us she was ...
Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. M Ghaemi, R ...
Jan 21, 2010 - Abstract We evaluated cognitive functions and mood in two groups of patients with multiple system atrophy (MSA) in order to determine the ...
(ref.39), antihistaminics (cetirizine) (ref.40), or GABA. B agonists (baclofen) (ref.38,41,42). Recently, increased CSP duration following tramadol application has ...
This figure was reprinted from the reference no. 15, with permission from IOS Press. Table 2. Relative frequencies of pathological subtypes of MSA in Japan and ...
with MSA-C. It comprised writer's cramp or dystonic arm posturing in .... Writers cramp. Good. 1. 4. 600. Craniocervical. P eak dose. Dystonic. 10. MSA-P. 64. 5.
lumbosacral region [157, 288], and minor or rarely severe loss of upper and ...... [10] Lyoo CH, Jeong Y, Ryu YH, Lee SY, Song TJ, Lee JH,. Rinne JO, Lee MS ...
Multiple System Atrophy Manifested by Bilateral Vocal Cord Palsy as an Initial Sign. Yuri Seo, M.D., Soomin Jeung, M.D., Heeyoung Yoon, M.D., Min-chul Kim, ...
the Carers Direct website at www.nhs.uk/ ... Besides offering expert support and advice, they will be in a good position
Table of Contents ...... 11. http://ageing.oxfordjournals.org/content/41/5/587.long .... space around the spinal cord vi
Two forms of MSA, are recognized, according to whether parkinsonian or cerebellar .... 7. http://www.mc.vanderbilt.edu/crc/aas/SDS_MSA_Award_winners.html.
Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Received: 8 March 2006 / Accepted: 22 April 2006 ...
Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial. Li et al. Li et al. Trials (2015) ...
Jun 1, 2013 - Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients. Tjalf Ziemssen ⢠Raimar ...
May 29, 2005 - Abstract. This study presents time-domain and frequen- cy-domain, multiple-input, multiple-output (MIMO) linear system identification ...
Feb 5, 2013 - Wassilios G Meissner, François Tison, Werner Poewe, for The ...... Deutsche Parkinson Vereinigung, International Parkinson Fond, Faber.
Flesch Reading Ease Test, Flesch-Kincaid Readability. (Covington 2008). Covington quotes Miller and Kintsch when he suggests that âthe idea density of a text ...
Treatment of multiple system atrophy using intravenous ... - Springer Link
Nov 1, 2012 - Abstract. Background: Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as ...
Novak et al. BMC Neurology 2012, 12:131 http://www.biomedcentral.com/1471-2377/12/131
RESEARCH ARTICLE
Open Access
Treatment of multiple system atrophy using intravenous immunoglobulin Peter Novak1*, Arlene Williams2, Paula Ravin1, Omar Zurkiya3, Amir Abduljalil4 and Vera Novak5
Abstract Background: Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia. Disease-modifying therapies are unavailable. Activation of microglia and production of toxic cytokines suggest a role of neuroinflammation in MSA pathogenesis. This pilot clinical trial evaluated safety and tolerability of intravenous immunoglobulin (IVIG) in MSA. Methods: This was a single-arm interventional, single-center, open-label pilot study. Interventions included monthly infusions of the IVIG preparation PrivigenW, dose 0.4 gram/kg, for 6 months. Primary outcome measures evaluated safety and secondary outcome measures evaluated preliminary efficacy of IVIG. Unified MSA Rating Scale (UMSARS) was measured monthly. Quantitative brain imaging using 3T MRI was performed before and after treatment. Results: Nine subjects were enrolled, and seven (2 women and 5 men, age range 55–64 years) completed the protocol. There were no serious adverse events. Systolic blood pressure increased during IVIG infusions (p
![MSA - The Multiple System Atrophy Coalition [PDF]](https://m.moam.info/img/260x300/msa-the-multiple-system-atrophy-coalition-pdf_647d82a9098a9e6c638b4644.jpg)
